Hence, anti-EGFR antibody therapy applied to CRC mice in the present study may reduce the splenic CD4+ T cell load via EGFR blockade on CD4+ T cells, as well as by induction of Fc-mediated effector cell cytotoxicity against CD4+ T cells [54]. This evidence concerns the gene EGFR and colorectal carcinoma.